Vyvgart (efgartigimod alfa-fcab) may be a safe and effective treatment for children and adolescents with juvenile myasthenia gravis (JMG), according to new real-world data from China. The study found that the therapy, developed by Argenx and currently approved for certain adults with…
News
Most children with juvenile myasthenia gravis (JMG) develop mild disease marked by eye muscle weakness, with more severe symptoms seen in those who are older when they start showing signs of disease, according to a single-center study in China. Data also suggested that blood levels of self-reactive antibodies against anti-acetylcholine…
People with myasthenia gravis (MG) are twice as likely to be diagnosed with other autoimmune diseases, both before and after an MG diagnosis, than a matched general population, a new study involving patients from Denmark found. This predisposition was particularly strong among patients younger than 50 — meaning those…
Enrollment is ongoing in a global, late-stage clinical trial testing the safety and efficacy of telitacicept in adults with generalized myasthenia gravis (gMG), with top-line data expected in the first half of next year, Vor Bio said. The Phase 3 UPSTREAM MG study (NCT06456580), previously known…
A late-stage clinical trial testing KYV-101, a CAR T-cell therapy for adults with hard-to-treat generalized myasthenia gravis (gMG), is still enrolling gMG patients to take part in its Phase 3 portion. This portion of the Phase 2/3 KYSA-6 trial (NCT06193889) is open to people with gMG, ages…
Treatment with Vyvgart (efgartigimod alfa) may safely and effectively treat acute exacerbations and symptom worsening in people with generalized myasthenia gravis (gMG), a real-world study in China shows. The treatment demonstrated a rapid onset of action, with significant improvements seen after the first dose, as well as a…
Starting statins — widely prescribed medications aimed at lowering levels of the fatty molecule cholesterol — may increase the risk of developing myasthenia gravis (MG) in people across different ethnicities, a new study reported. The risk appears highest during the first six months of treatment and was more pronounced…
Ocular myasthenia gravis (OMG) patients with abnormalities in the thymus gland, antibodies against the AChR protein, or a history of smoking are at a higher risk of progression to generalized myasthenia gravis, according to a study in Thailand. Higher doses of pyridostigmine (sold as Mestinon, among others, with generics…
The immunosuppressive medications azathioprine and mycophenolate mofetil are similarly effective at controlling symptoms of generalized myasthenia gravis (gMG), but mycophenolate mofetil tends to act more quickly, according to a study in the U.S. Data also indicated that both medications were generally more effective when combined with corticosteroids, a…
Surgical removal of the thymus, or thymectomy, significantly improves nerve-muscle communication and eases symptoms and their impact on daily activities in children and adolescents with juvenile myasthenia gravis (JMG), a small U.S. study showed. After thymectomy, young patients not only showed measurable improvements in how efficiently their nerves…
Recent Posts
- Vyvgart may fill gap in medications for juvenile MG: Real-world study
- Antibody levels may help track disease severity in children with MG
- I’m learning which conversations are worth having, and which ones aren’t
- Guest Voice: A strabismus diagnosis may have been my MG journey’s start
- MG patients 2 times as likely to have other autoimmune diseases